Grand Rounds
Dihydropyrimidine Dehydrogenase Deficiency: To Screen or Not to Screen?
Wendy H. Vogel,(1) MSN, FNP, AOCNP®, Ahmed Minhas,(2) MD, and Steven Baumrucker,(1) MD
From (1)Wellmont Cancer Institute, Kingsport, Tennessee; (2)East Tennessee State University, Johnson City, Tennessee
Authors’ disclosures of conflicts of interest are found at the end of this article.
Correspondence to: Wendy H. Vogel, MSN, FNP, AOCNP®, Wellmont Cancer Institute, 4485 West Stone Drive, Kingsport, TN 37660.
E-mail: wendyvogel55@gmail.com
J Adv Pract Oncol 2020;11(1):68–73 |
https://doi.org/10.6004/jadpro.2020.11.1.4 |
© 2020 Harborside™
ABSTRACT
5-fluorouracil (5-FU) and its prodrug capecitabine are frequently prescribed in oncology. While usually well tolerated, toxicity can be severe, and even life-threatening. A dihydropyrimidine dehydrogenase (DPD) deficiency can cause severe toxicity. Current testing for DPD deficiency does not meet the criteria for a routine screening test prior to 5-FU therapy. A case study of a fatality secondary to capecitabine toxicity is reviewed and literature is examined regarding general screening for DPD deficiency.
For access to the full length article, please
sign in.
